Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · IGC Pharma, Inc. (IGC)

IGC Pharma extends O-Bank loan facility, fee rises to $60,000 from $48,000

Neutral Impact 2 of 5 financing Written later

IGC Pharma entered into an amendment on June 5, 2026 to extend its Master Loan and Security Agreement with O-Bank Co., Ltd. of Taiwan, keeping a maximum aggregate facility limit of $12,000,000. Apart from the facility fee rising from $48,000 to $60,000, the material terms are substantially unchanged from the June 24, 2025 facility letter, so the change is modest for shareholders.

Key points

  • Amendment dated June 5, 2026 extends the Master Loan and Security Agreement and General Banking Facility Letter with O-Bank Co., Ltd.
  • Maximum aggregate facility limit is $12,000,000.
  • Facility fee increases from $48,000 to $60,000.
  • Other material terms remain substantially unchanged from the 2025 facility letter.

The filing

CompanyIGC Pharma, Inc. (IGC)
Form8-K, current report
Filed with the SECJun 8, 2026, 4:03 PM ET
Accession number0001185185-26-002410

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.